Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens

The primary purpose is to determine bioavailability of Bazedoxifene/conjugated estrogen formulations for future testing purposes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

45 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy, post menopausal women ages 45 to 70

Exclusion criteria

Male subjects

Treatment and study plan

bazedoxifene/conjugated estrogens combination

Drug

Primary outcomes

Bioavailability

Secondary outcomes

Safety & tolerability

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

An Open-Label, Single-Dose, Non-Randomized, 4-Period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women

Important dates

Study start: 2007
Study completion: 2007
First posted: Oct 29, 2007
Registry last updated: Dec 27, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed